UCLA Tumor Immunology Institutional Training Grant

加州大学洛杉矶分校肿瘤免疫学机构培训补助金

• 批准号: 10712108
• 负责人: Steven M. Dubinett
• 金额: $ 46.03万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-07-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712108
• 关键词: Grant; Institution; Training; tumor immunology

PROJECT SUMMARY Despite decades of research, and the ravages of a recent global viral pandemic, cancer will unfortunately remain the Number One killer of adults under 85. Thus, there is a substantial need for new therapies based on mechanisms that the non-malignant cellular microenvironment uses to prevent and control cancer. In direct response to this need, our A1-revised competitive renewal application seeks to continue the highly successful, multidisciplinary UCLA Tumor Immunology Training Program (UCLA TITP). The TITP, as the sole training vehicle at UCLA that integrates oncology with immunology, aims to provide comprehensive, interdisciplinary training to graduate students and post-doctoral fellows at the cancer-immune system interface to foster immune approaches that prevent and control cancer. An equally important aim is to prepare a well-trained and highly diverse cohort of experts using augmented professional development activities for productive careers in a rapidly evolving job market as leaders in academic and commercial tumor immunology. It is an extraordinary time in oncology as advances in tumor immunology are leading progress against intractable cancers, with cell engineering, immune checkpoint inhibition, gene editing, computational biology, machine learning/AI, and multiple interdisciplinary approaches at the cutting-edge. The TITP has superb institutional synergies with the NCI-designated Jonsson Comprehensive Cancer Center (JCCC), the UCLA Clinical Science Translational Institute (CTSI), the UCLA Parker Institute for Cancer Immunotherapy (PICI), the Graduate Programs in Bioscience (GPB), the UCLA-Caltech Medical Scientist Training Program (MSTP), and other exceptional campus research centers. The program Co-Directors and Associate Director have outstanding records of research productivity and trainee mentoring. TITP recruits trainees from a large, unique and diverse pool with emphasis placed on research integrity training, mentoring, and outreach to enhance underrepresented scientist participation. We propose to support eight trainees (four pre- and four post-docs, up to three years, with strong progress) in a structured program supervised by highly productive faculty. For this period, with an updated mentor corps, training focuses in three high-priority tracts: Cancer Immunotherapy, Immuno-Oncology, and Tumor Microenvironment. About 90% of past trainees continue cancer research careers in academia or industry. TITP leaders, a preeminent refreshed EAB, and four internal Program Advisors perform ongoing rigorous evaluations with input from trainees/faculty to strengthen the program. A key required element is a pre- and post-doc curriculum that builds knowledge in basic, translational, and clinical tumor immunology research. Other strong components include a monthly Research-in-Progress seminar series, annually updated Individual Development Plans (IDPs), an annual (typically summertime) Program Retreat, and major campus symposia on cancer and immunology. Altogether, the TITP infrastructure supports an exciting, coherent, interactive program that uniquely educates graduate and post-doctoral trainees in tumor immunology at UCLA.

项目摘要 尽管经过几十年的研究，以及最近全球病毒大流行的破坏，癌症将不幸地 仍然是85岁以下成年人的头号杀手因此，存在对基于以下的新疗法的实质性需求： 非恶性细胞微环境用于预防和控制癌症的机制。直接 为了满足这一需求，我们的A1修订版竞争性续期申请寻求继续非常成功， UCLA Tumor Immunology Training Program（UCLA TITP）TITP作为唯一的培训 加州大学洛杉矶分校的一个工具，将肿瘤学与免疫学相结合，旨在提供全面的，跨学科的 对研究生和博士后研究员进行癌症-免疫系统界面的培训， 预防和控制癌症的免疫方法。另一个同样重要的目标是， 高度多样化的专家群体，利用扩大的专业发展活动， 作为学术和商业肿瘤免疫学的领导者，迅速发展的就业市场。这是一个非同寻常的 随着肿瘤免疫学的进步正在引领治疗难治性癌症的进展， 工程，免疫检查点抑制，基因编辑，计算生物学，机器学习/AI，以及 多学科方法的前沿。TITP具有卓越的机构协同作用， NCI-designated Jonsson Comprehensive Cancer Center（JCCC），the UCLA Clinical Science Translational 加州大学洛杉矶分校帕克癌症免疫治疗研究所（PICI）， 生物科学（GPB），加州大学洛杉矶分校-加州理工学院医学科学家培训计划（MSTP），以及其他特殊的 校园研究中心。该计划的联合主任和副主任有杰出的记录， 研究生产力和实习生指导。TITP从一个庞大，独特和多样化的人才库中招募学员， 强调研究诚信培训、指导和外联，以提高代表性不足的科学家的能力 参与的我们建议支持八名受训人员（四名博士前和四名博士后，最长三年， 进步）在一个结构化的程序由高生产力的教师监督。在这段时间里， 导师团，培训重点在三个高度优先的领域：癌症免疫治疗，免疫肿瘤学， 肿瘤微环境大约90%的过去的学员继续在学术界或癌症研究事业 行业TITP领导人，一个卓越的更新EAB，和四个内部计划顾问执行持续 严格的评估与学员/教师的投入，以加强计划。一个关键的必需元素是 建立基础，转化和临床肿瘤免疫学知识的前和博士后课程 research.其他强有力的组成部分包括每月的研究进展研讨会系列，每年更新 个人发展计划（IDPs），年度（通常是夏季）计划务虚会和主要校园 癌症和免疫学研讨会。总之，TITP基础设施支持一个令人兴奋的，连贯的， 互动程序，独特的教育研究生和博士后学员在肿瘤免疫学在加州大学洛杉矶分校。

项目成果

Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes.

• DOI: 10.1158/1078-0432.ccr-22-1491
• 发表时间: 2023-04-14
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.

马来酰亚胺缀合显着增强了人和鼠独特型-KLH 疫苗的免疫原性。

• DOI: 10.1016/j.molimm.2008.10.020
• 发表时间: 2009-01
• 期刊: Molecular immunology
• 影响因子: 3.6
• 作者: Kafi K;Betting DJ;Yamada RE;Bacica M;Steward KK;Timmerman JM
• 通讯作者: Timmerman JM

Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.

• DOI: 10.3390/cells12192404
• 发表时间: 2023-10-04
• 期刊: Cells
• 影响因子: 6

Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma.

• DOI: 10.3390/cancers12092389
• 发表时间: 2020-08-24
• 期刊: Cancers
• 影响因子: 5.2
• 作者: Graham DS;van Dams R;Jackson NJ;Onyshchenko M;Eckardt MA;DiPardo BJ;Nelson SD;Chmielowski B;Shabason JE;Singh AS;Eilber FC;Kalbasi A
• 通讯作者: Kalbasi A

Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach.

利用新型 RNA 干扰筛选方法鉴定了 MyD88 依赖性促炎细胞因子产生的抑制剂。

• DOI: 10.1371/journal.pone.0007029
• 发表时间: 2009
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Cho,JohnS;Kim,YunC;Morrison,SherieL
• 通讯作者: Morrison,SherieL